Management of Chronic Liver Disease in Surgical Patients: A Critical Care Perspective

Dr Neeraj Manikath , claude.ai

Abstract

Patients with chronic liver disease (CLD) undergoing surgery present unique challenges that significantly impact perioperative morbidity and mortality. The intersection of hepatic dysfunction, portal hypertension, and surgical stress creates a complex clinical scenario requiring meticulous preoperative assessment, intraoperative vigilance, and intensive postoperative monitoring. This review synthesizes current evidence on risk stratification, coagulation management, and prevention of hepatic encephalopathy in surgical patients with CLD, providing practical insights for intensivists managing these high-risk patients.

Introduction

Chronic liver disease affects approximately 4.5 million adults in the United States alone, with cirrhosis representing the 12th leading cause of death worldwide. As the prevalence of non-alcoholic fatty liver disease (NAFLD) and viral hepatitis continues to rise, critical care physicians increasingly encounter patients with varying degrees of hepatic dysfunction requiring surgical intervention. The 30-day mortality for patients with cirrhosis undergoing elective surgery ranges from 10-30%, escalating to 50-80% for emergency procedures.

The pathophysiological derangements in CLD—including synthetic dysfunction, portal hypertension, splanchnic vasodilation, renal impairment, and immune dysregulation—are profoundly exacerbated by surgical stress, anesthesia, and blood loss. Understanding the nuanced approach to perioperative management is essential for optimizing outcomes in this vulnerable population.

Risk Stratification Using MELD and Child-Pugh Scores

The Child-Pugh Classification: Historical Foundation

The Child-Pugh score, developed in 1964 and modified in 1973, remains a cornerstone of hepatic risk assessment. This five-variable system (bilirubin, albumin, INR, ascites, encephalopathy) categorizes patients into Class A (5-6 points), B (7-9 points), or C (10-15 points), correlating with surgical mortality rates of approximately 10%, 30%, and 80%, respectively.

Pearl: Child-Pugh Class A patients generally tolerate elective surgery well, but even minor hepatic decompensation (Class B) dramatically increases perioperative risk. The presence of ascites and encephalopathy—subjective variables—makes this score particularly useful for assessing functional hepatic reserve beyond laboratory parameters alone.

Oyster: The Child-Pugh score has significant limitations. It lacks discriminatory power at the extremes, uses arbitrary cutoffs, and includes subjective assessments of ascites and encephalopathy that may vary between observers. Additionally, it was originally designed for prognosis in cirrhotic patients with variceal bleeding, not surgical risk prediction.

The MELD Score: Objective Refinement

The Model for End-Stage Liver Disease (MELD), introduced in 2001 and refined in 2016 (MELD-Na), provides an objective, continuous variable for mortality prediction:

MELD = 3.78×ln[bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[creatinine (mg/dL)] + 6.43

MELD-Na incorporates serum sodium (values 125-137 mEq/L), improving prognostic accuracy in patients with hyponatremia, a common complication of advanced cirrhosis.

Multiple studies have demonstrated superior predictive capability of MELD for perioperative mortality:

MELD <10: mortality <5%
MELD 10-15: mortality 10-15%
MELD 15-20: mortality 20-30%
MELD >20: mortality >50%

Hack: Use the "rule of 10s" for quick bedside risk assessment: Each 10-point increase in MELD roughly doubles the perioperative mortality risk. A MELD >15 should prompt serious consideration of non-operative management or intensive perioperative optimization.

Comparative Utility and Combined Approaches

Meta-analyses comparing Child-Pugh and MELD consistently demonstrate MELD's superior discriminatory ability for short-term mortality prediction. However, Child-Pugh remains valuable for capturing functional manifestations not reflected in MELD (ascites, encephalopathy).

Pearl: Use both scores complementarily. MELD-Na ≥12 combined with Child-Pugh Class B or C identifies the highest-risk cohort. Consider multidisciplinary consultation with hepatology for any patient with MELD >12 or Child-Pugh Class B/C facing non-hepatic surgery.

Procedure-Specific Risk Stratification

Risk varies dramatically by surgical procedure:

Low-risk procedures (hernia repair, dental): Generally safe even in Child-Pugh B
Moderate-risk procedures (cholecystectomy, appendectomy): Consider laparoscopic approach when possible
High-risk procedures (cardiac surgery, major abdominal): Extremely high mortality in Child-Pugh C; consider only if emergent

Oyster: Emergency surgery mortality in cirrhotic patients approaches 80% regardless of risk scores. When facing emergency surgery, focus on damage control principles: abbreviated procedures, early ICU transfer, and aggressive postoperative optimization.

Emerging Risk Models

The Mayo Clinic has proposed combining MELD with ASA class and age into integrated models. The MELDPlus score incorporates albumin and total cholesterol, showing improved discrimination. The VOCAL-Penn score (Veterans Outcomes and Costs Associated with Liver disease) adds BMI, operative indication, and albumin to MELD-Na, demonstrating superior performance for surgical mortality prediction.

Hack: For patients undergoing abdominal surgery specifically, the MELD-Plus-7 score (MELD plus albumin <2.5 g/dL = +7 points) has shown excellent calibration. An online calculator is available at www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease.

Managing Coagulopathy and Thrombocytopenia

Understanding the Rebalanced Hemostasis

The traditional view of cirrhotic patients as "auto-anticoagulated" is outdated. Modern understanding recognizes a rebalanced but precarious hemostatic state:

Procoagulant deficiencies: Decreased synthesis of factors II, V, VII, IX, X, XI, and protein C/S
Anticoagulant deficiencies: Reduced protein C, protein S, antithrombin
Thrombocytopenia: Splenic sequestration and decreased thrombopoietin production
Qualitative platelet dysfunction: Uremia, medications, acquired storage pool deficiency
Enhanced fibrinolysis: Decreased clearance of tPA, reduced α2-antiplasmin

Pearl: Standard coagulation tests (PT/INR, aPTT) do not predict bleeding risk accurately in cirrhotic patients. These tests measure only procoagulant factors and ignore compensatory mechanisms. The thromboelastography (TEG) or rotational thromboelastometry (ROTEM) provide a more comprehensive assessment of hemostasis.

Preoperative Assessment

Baseline Laboratory Evaluation:

PT/INR, aPTT, fibrinogen
Platelet count
Consider TEG/ROTEM if available
Factor levels only if specific deficiency suspected

Oyster: An elevated INR in cirrhotic patients reflects reduced Factor VII synthesis but does NOT equate to bleeding risk as in warfarin anticoagulation. Factor VII is the first to decline due to its short half-life (6 hours), but balanced reductions in protein C (similar half-life) maintain hemostatic equilibrium.

Perioperative Coagulopathy Management

Platelet Transfusion

Threshold approach:

Major surgery/high bleeding risk: Maintain platelets >50,000/μL
Neurosurgery/ophthalmic surgery: Consider >75,000/μL
Minor procedures: >30,000/μL often sufficient

Hack: Thrombopoietin receptor agonists (avatrombopag, lusutrombopag) represent a paradigm shift. When given 10-13 days before elective procedures, these oral agents can increase platelet counts, potentially reducing or eliminating the need for platelet transfusion. FDA-approved for thrombocytopenia in CLD patients undergoing procedures. Typical dosing: avatrombopag 60 mg daily × 5 days, starting 10-13 days before procedure.

Pearl: One unit of platelets increases count by approximately 5,000-10,000/μL. However, splenic sequestration in portal hypertension reduces the increment. Consider transfusing closer to procedure time to maximize effect.

Fresh Frozen Plasma (FFP) and Coagulation Factor Replacement

The FFP Controversy:

Large volumes required to correct INR (10-20 mL/kg)
Transient effect (hours)
Volume overload risk
May worsen portal hypertension

Evidence-based approach:

Do NOT routinely correct INR unless active bleeding or extremely high risk
INR >2.5 before major surgery: Consider factor replacement
Active bleeding: Target INR <1.8 using goal-directed therapy

Hack: Prothrombin Complex Concentrates (PCC) offer rapid, concentrated factor replacement without volume overload. Four-factor PCC contains factors II, VII, IX, X plus protein C and S. Typical dosing: 25-50 units/kg (based on INR and body weight). Onset within 30 minutes, avoiding the pulmonary edema risk of FFP.

Alternative: Recombinant Factor VIIa (rFVIIa) at 20-90 μg/kg can rapidly correct coagulopathy but carries thrombotic risk. Reserve for refractory bleeding unresponsive to other measures. Cost (~$10,000 per dose) limits routine use.

Fibrinogen Replacement

Target fibrinogen >100-150 mg/dL perioperatively. Cryoprecipitate (10-15 mL/kg raises fibrinogen ~100 mg/dL) or fibrinogen concentrate (30-60 mg/kg) can be used.

Pearl: Fibrinogen levels <100 mg/dL significantly impair clot formation. Check fibrinogen if diffuse oozing occurs despite correcting other parameters. TEG/ROTEM showing low amplitude directly reflects low fibrinogen.

Antifibrinolytic Agents

Tranexamic acid (TXA) at 10-15 mg/kg loading dose followed by 1-5 mg/kg/hr infusion inhibits fibrinolysis. Particularly useful in cardiac surgery or when enhanced fibrinolysis is documented on TEG/ROTEM.

Oyster: Avoid TXA in patients with active thrombosis or DIC. While generally safe, theoretical thrombotic risk exists given the already rebalanced hemostasis.

Intraoperative Management

Viscoelastic-Guided Algorithm:

Obtain baseline TEG/ROTEM
Reaction time prolonged → FFP or PCC
Angle decreased/MA decreased → Fibrinogen (cryoprecipitate/fibrinogen concentrate)
MA decreased with normal fibrinogen → Platelet transfusion
LY30 increased → Tranexamic acid

Hack: Cell salvage (autotransfusion) can reduce allogeneic transfusion requirements but is controversial in hepatic surgery due to concerns about returning inflammatory mediators. Modern leukocyte-reduction filters mitigate this concern. Use when blood loss >1000 mL anticipated.

Postoperative Hemorrhage Management

Stepwise approach:

Assess severity and source (surgical vs. coagulopathic)
Return to OR if surgical bleeding suspected
TEG/ROTEM-guided factor replacement
Consider desmopressin (DDAVP) 0.3 μg/kg for platelet dysfunction
Recombinant Factor VIIa as last resort

Pearl: Sepsis-induced coagulopathy can complicate postoperative management. Monitor for DIC (falling platelets, low fibrinogen, elevated D-dimer). Treatment focuses on infection control; heparin use is controversial.

Preventing and Treating Hepatic Encephalopathy Postoperatively

Pathophysiology and Risk Factors

Hepatic encephalopathy (HE) results from accumulation of neurotoxic substances—primarily ammonia—that bypass hepatic clearance via portosystemic shunting. Postoperative HE occurs in 20-40% of cirrhotic surgical patients, significantly increasing mortality and length of stay.

Precipitating factors in surgical patients:

Gastrointestinal bleeding (protein load)
Dehydration/electrolyte disturbances
Infection/sepsis
Medications (opioids, benzodiazepines, anticholinergics)
Constipation
Azotemia
Metabolic alkalosis
Hypoxia/hypercapnia

Oyster: Many anesthetic agents and analgesics are hepatically metabolized and can precipitate or worsen HE. Avoid long-acting benzodiazepines (diazepam, midazolam has prolonged half-life in cirrhosis) and prefer short-acting alternatives.

Preoperative Prevention Strategies

Optimization of Baseline HE

Ensure patients are on optimal lactulose therapy preoperatively:

Target: 2-3 soft bowel movements daily
Typical dose: 15-30 mL two to three times daily, adjusted to effect
Alternative: Lactitol 0.5-0.7 g/kg/day in divided doses

Pearl: Rifaximin (550 mg twice daily) reduces HE recurrence by 58% and is the only FDA-approved maintenance therapy. Combining rifaximin with lactulose shows superior efficacy compared to either agent alone. Ensure continuation throughout perioperative period if patient on chronic therapy.

Nutritional Optimization

Hack: Contrary to historical teaching, protein restriction is detrimental in cirrhotic patients. Provide 1.2-1.5 g/kg/day of protein, preferably branched-chain amino acid (BCAA)-enriched formulas. BCAAs (leucine, isoleucine, valine) are metabolized in muscle rather than liver and may reduce ammonia production while improving nutritional status.

Late evening snack (50g carbohydrate) reduces protein catabolism overnight and improves nitrogen balance. Simple intervention with significant impact.

Identifying and Treating Precipitants

Preoperative checklist:

Screen for infection (SBP, UTI, pneumonia)
Correct electrolyte abnormalities (especially hyponatremia, hypokalemia)
Assess volume status and renal function
Optimize bowel regimen
Review medications for HE triggers

Intraoperative Considerations

Anesthetic Management

Preferred agents:

Induction: Propofol (despite hepatic metabolism, single dose acceptable), etomidate if hemodynamically unstable
Maintenance: Sevoflurane or desflurane (minimal hepatic metabolism)
Neuromuscular blockade: Cisatracurium (Hofmann elimination, not organ-dependent)
Analgesia: Remifentanil (esterase metabolism, ultra-short acting)

Avoid:

Repeated doses of midazolam
Long-acting opioids (morphine, hydromorphone metabolites accumulate)
Halothane (hepatotoxic)

Pearl: Regional anesthesia (epidural, spinal) reduces opioid requirements and may decrease HE risk. Consider multimodal analgesia with acetaminophen (≤2g/day in cirrhosis), NSAIDs (avoid if renal impairment), and regional techniques.

Maintaining Cerebral Homeostasis

Avoid hypotension (maintain MAP >65 mmHg)
Prevent hypoxia (target SpO₂ >94%)
Avoid hypercarbia (increases cerebral ammonia uptake)
Maintain normoglycemia (hypoglycemia precipitates HE)
Judicious fluid management (avoid both hypovolemia and hypervolemia)

Hack: Goal-directed fluid therapy using stroke volume variation or pulse pressure variation optimizes fluid administration, avoiding the Scylla of hypovolemia (renal failure, HE) and Charybdis of hypervolemia (ascites, pulmonary edema). Target SVV <10-13%.

Postoperative Prevention and Management

Universal Prophylaxis

Lactulose continuation/initiation:

If patient on lactulose preoperatively: Resume immediately when bowel function returns (may give via NGT)
If not previously on lactulose: Consider prophylactic lactulose 15-30 mL every 8 hours for high-risk patients (MELD >15, prior HE, major surgery)

Pearl: Rifaximin continuation is essential for patients on chronic therapy. May crush tablets and administer via NGT. Start rifaximin 550 mg BID prophylactically in patients with prior HE history undergoing major surgery.

Early Recognition and Grading

West Haven Criteria:

Grade 1: Altered sleep rhythm, mild confusion, irritability (subtle, often missed)
Grade 2: Lethargy, disorientation to time, inappropriate behavior, asterixis
Grade 3: Somnolent but arousable, disorientation to place, hyperreflexia
Grade 4: Coma, decerebrate posturing

Hack: Use Number Connection Test or Stroop Test for objective assessment of Grade 1 HE. Grade 1 HE may be dismissed as "postoperative delirium" but requires specific treatment. Asterixis is present in only 50-60% of HE cases—absence does not exclude diagnosis.

Oyster: Postoperative HE can be challenging to distinguish from postoperative delirium, particularly Grade 1-2 HE. Key distinguishing features: asterixis (when present), hyperammonemia (though ammonia levels correlate poorly with severity), and response to lactulose/rifaximin.

Treatment Algorithm for Overt HE

Step 1: Identify and Treat Precipitants

Infection (blood/urine/ascitic fluid cultures, empiric antibiotics if suspicious)
GI bleeding (NG lavage, hemoglobin monitoring)
Constipation (abdominal imaging if needed)
Medications (discontinue offending agents)
Electrolyte/metabolic derangements
Renal dysfunction/volume depletion

Step 2: Lactulose Intensification

Oral/NGT: 30 mL every 2-4 hours until bowel movement, then titrate to 2-3 soft stools daily
Rectal (if ileus/NGT not feasible): 300 mL lactulose in 700 mL water retention enema, repeat every 4-6 hours

Step 3: Add/Optimize Rifaximin

550 mg twice daily (or three times daily if severe)
Reduces ammonia-producing gut bacteria

Step 4: Consider Additional Therapies

L-ornithine L-aspartate (LOLA):

Enhances ammonia metabolism via urea cycle and glutamine synthesis
IV: 20-40g/day continuous infusion (Europe/Asia; not FDA-approved in US)
Oral: 9-18g/day in divided doses
Meta-analyses show significant benefit in overt HE

Zinc supplementation:

220 mg zinc sulfate twice daily
Zinc is a cofactor for urea cycle enzymes
Cirrhotic patients often zinc-deficient
Long-term benefit, not acute treatment

Branched-chain amino acids:

IV or oral supplementation
May be beneficial when other treatments insufficient

Polyethylene glycol (PEG):

4L PEG solution administered over 4 hours
Acts as aggressive cathartic
Small trials show faster HE resolution than lactulose alone
Useful alternative/adjunct when lactulose inadequate

Step 5: Refractory HE

Neomycin or metronidazole:

Neomycin 500-1000mg twice daily (ototoxicity/nephrotoxicity limit use)
Metronidazole 250mg three times daily (neuropathy risk >2 weeks)
Second-line due to side effect profile

Flumazenil:

Benzodiazepine antagonist
0.2mg IV bolus, repeat up to 1mg total
Consider if benzodiazepine exposure or if GABA-mediated HE suspected
Response suggests diagnosis; may provide temporary improvement

Protein restriction:

Generally discouraged but may briefly restrict to 0.5g/kg/day for 24-48 hours in refractory cases
Prolonged restriction worsens malnutrition and outcomes

Grade 4 HE: Acute Liver Failure Considerations

Grade 4 HE with coma requires ICU-level care:

Airway protection/mechanical ventilation
ICP monitoring if acute liver failure suspected (not routinely done in cirrhosis)
Avoid hyperventilation unless signs of herniation (worsens cerebral perfusion)
Mannitol/hypertonic saline if cerebral edema (rare in chronic cirrhosis)
Ammonia scavenging: IV L-ornithine L-aspartate or consider continuous renal replacement therapy (CRRT) for hyperammonemia >200 μmol/L
Liver transplant evaluation: Grade 4 HE postoperatively may indicate acute-on-chronic liver failure; expedited transplant evaluation if appropriate

Pearl: Molecular adsorbent recirculating system (MARS) or Prometheus can provide temporary support as bridge to transplant or recovery by removing albumin-bound and water-soluble toxins. Limited availability restricts use to specialized centers.

Special Postoperative Considerations

Pain management without precipitating HE:

Acetaminophen ≤2g/day (safe even in cirrhosis at this dose)
Regional analgesia (epidural, peripheral nerve blocks)
Tramadol (avoid if CrCl <30)
Fentanyl IV (short-acting, preferred opioid)
Avoid: Morphine (toxic metabolite accumulation), long-acting opioids

Infection surveillance:

High index of suspicion (cirrhotic patients may not mount typical fever/leukocytosis)
Diagnostic paracentesis if ascites present (SBP often clinically silent)
Empiric antibiotics if HE worsens without clear precipitant

Nutritional support:

Resume enteral nutrition early (within 24-48 hours)
BCAA-enriched formulas preferred
Parenteral nutrition if enteral not feasible (higher infection risk)

Practical Approach: Putting It All Together

Preoperative Optimization Checklist

Risk Stratification: Calculate MELD-Na and Child-Pugh; if MELD >15 or Child-Pugh B/C, multidisciplinary planning
Hepatology consultation for optimization (MELD >12, ascites, prior decompensation)
Cardiac evaluation: Consider dobutamine stress echo (high cardiac risk)
Nutritional assessment: Optimize protein intake, correct deficiencies
Coagulation baseline: TEG/ROTEM if available; consider TPO agonists if platelets <50,000 and elective surgery
HE optimization: Ensure on lactulose ± rifaximin if history of HE
Ascites management: Large-volume paracentesis if tense ascites (improves respiratory mechanics)
Renal function: Assess for hepatorenal syndrome; optimize volume status
Infection screening: Spontaneous bacterial peritonitis, urinary tract infection
Informed consent: Realistic discussion of risks

Intraoperative Pearls

Anesthetic technique: Regional > general anesthesia when feasible
Minimize blood loss: Meticulous hemostasis, cell salvage, TEG-guided transfusion
Hemodynamic stability: Avoid hypotension (worsens hepatic perfusion and renal function)
Fluid management: Goal-directed, balanced crystalloids (avoid NS, causes hyperchloremic acidosis)
Temperature management: Maintain normothermia (hypothermia worsens coagulopathy)
Surgical approach: Laparoscopic preferred (reduced stress response, lower morbidity)

Postoperative ICU Management

Monitoring:

Continuous hemodynamic monitoring (arterial line, consider central access)
Strict intake/output (AKI common)
Daily labs: CBC, CMP, coags, ammonia if altered mental status
Clinical assessment for ascites, bleeding, infection, HE every shift

Prophylaxis:

Lactulose continuation/initiation
DVT prophylaxis (sequential compression devices; pharmacologic with caution)
Stress ulcer prophylaxis (PPI)
Early mobilization

Nutritional support:

Resume enteral nutrition early
1.2-1.5 g/kg protein daily
BCAA-enriched if HE develops

Complications surveillance:

Acute kidney injury (daily creatinine; consider CRRT if AKI + volume overload)
Infection (low threshold for cultures and empiric antibiotics)
Hepatic encephalopathy (early recognition and treatment)
Bleeding (clinical monitoring, serial hemoglobin)

Conclusions

The management of chronic liver disease in surgical patients demands a comprehensive, multidisciplinary approach integrating preoperative risk stratification, intraoperative vigilance, and intensive postoperative monitoring. Key principles include:

Risk stratification using both MELD-Na and Child-Pugh provides complementary prognostic information; MELD >15 identifies highest-risk patients requiring intensive optimization
Coagulopathy management has evolved beyond empiric FFP administration to TEG/ROTEM-guided, targeted factor replacement, with thrombopoietin agonists and PCCs offering novel strategies
Hepatic encephalopathy prevention requires maintaining lactulose therapy perioperatively, avoiding precipitants (especially benzodiazepines and long-acting opioids), and early aggressive treatment when HE develops

The intensivist's role extends beyond managing acute decompensation to orchestrating a coordinated perioperative strategy that begins in the preoperative optimization phase and continues through rehabilitation. As surgical techniques advance and our understanding of hepatic pathophysiology deepens, outcomes continue to improve—but cirrhotic patients undergoing surgery remain among the highest-risk cohorts in perioperative medicine. Vigilance, expertise, and evidence-based management are essential to optimize outcomes in this challenging population.

References

Teh SH, Nagorney DM, Stevens SR, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007;132(4):1261-1269.
Northup PG, Wanamaker RC, Lee VD, Adams RB, Berg CL. Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg. 2005;242(2):244-251.
Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797-805.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649.
Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878-885.
Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.
Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000-1007.
Kallis Y, Robson AJ, Fallowfield JA, et al. Rebalancing haemostasis in patients with acute liver injury using thromboelastography-guided therapy. Liver Int. 2017;37(7):1019-1028.
Demetriades D, Kimbrell B, Salim A, et al. Trauma deaths in a mature urban trauma system: is "trimodal" distribution a valid concept? J Am Coll Surg. 2005;201(3):343-348.
Stravitz RT. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol. 2012;8(8):513-520.
Patel IJ, Davidson JC, Nikolic B, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727-736.
Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology. 2006;44(4):1039-1046.
Pereira J, Accatino L, Alfaro J, et al. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol. 1995;50(3):173-178.
Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology. 2008;47(5):1604-1614.
Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol. 2006;12(48):7725-7736.
Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716-724.
Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology. 2019;70(4):1336-1348.
Shamseddeen H, Patidar KR, Ghabril M, et al. The role of thrombopoietin receptor agonists in the management of thrombocytopenia in chronic liver disease. Clin Liver Dis (Hoboken). 2019;14(5):177-180.
Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion. 2006;46(8):1279-1285.
Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-1243.
Dara SI, Rana R, Afessa B, Moore SB, Gajic O. Fresh frozen plasma transfusion in critically ill medical patients with coagulopathy. Crit Care Med. 2005;33(11):2667-2671.
Youssef WI, Salazar F, Dasarathy S, Beddow T, Mullen KD. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98(6):1391-1394.
Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease

Sunday, November 9, 2025